Scientific events

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that abstracts related to lacutamab health-related quality of life and translational data from the...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that new preclinical data supporting the clinical development of its proprietary next generation...

Phase 1 data for IPH5201, a CD39-blocking monoclonal antibody, as monotherapy or in combination with durvalumab, in advanced solid tumors to be presented by partner AstraZeneca Preclinical data...

Innate to present new Phase 2 data on the combination of monalizumab, cetuximab and durvalumab in head and neck cancer in an oral presentation ANKET TM to be highlighted in ESMO IO educational session...

Preliminary results of IPH5401 STELLAR-001, a dose escalation Phase I study in patients with advanced solid tumors 1-year survival data of monalizumab in combination with cetuximab in h ead and neck...

Differentiating profile of IPH4102 confirmed: high and durable response, favorable safety profile with long-term follow-up and substantial improvement in quality of life Innate Pharma expects to...

Management to host KOL call on updated data from the ongoing Phase II trial of monalizumab and cetuximab on Monday, October 22, 4pm CEST (10 am EDT) Innate Pharma SA (the “Company” - Euronext Paris...

Oral presentation on data with longer follow-up of dose escalation patients and new data from cohort expansion in the Phase I study at the EORTC CLTF 2018 Meeting IPH4102 showed encouraging clinical...

Updated long term follow-up data and new data from cohort expansion in the Phase I of IPH4102 in advanced CTCL at the EORTC CLTF 2018 Meeting Updated data from Phase I/II fully-enrolled study of...